吉贝尔：在研抗抑郁一类新药JJH201501 III期临床试验结果积极

Core Viewpoint - The clinical trial results for the antidepressant drug JJH201501 developed by the company show significant efficacy at 10mg and 15mg dosage groups compared to the placebo group, and are comparable to the 20mg group of hydrobromide venlafaxine tablets, with good safety and tolerability [2] Summary by Categories - Clinical Trial Results - The III phase clinical trial results indicate that the 10mg and 15mg dosage groups of JJH201501 have significantly better efficacy than the placebo group [2] - The efficacy of JJH201501 at these dosages is comparable to that of the 20mg group of hydrobromide venlafaxine tablets [2] - The safety and tolerability of JJH201501 are reported to be good [2] - Future Plans - The company plans to submit a New Drug Application (NDA) after completing the III phase clinical trial [2]